An interventional study of Supera Peripheral Stent System treatment group and Endarterectomy treatment group in Peripheral Arterial Disease, sponsored by KANDO Research. Active, not recruiting at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by KANDO Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Peripheral Arterial Disease with a site in Belgium — 8 open to participants now, 17 under way, 3 of them phase 3. Peripheral Arterial Disease · Belgium.
Among the 85 studies in Peripheral Arterial Disease with a site in Belgium, this one is the 16th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2020, is one of 34 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 66th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →8 of the 85 studies in Peripheral Arterial Disease with a site in Belgium are open now. Recruiting first, the newest first:
KANDO Research · Sites in Belgium
Ages 18–99
Intervascular · Sites in Belgium, United States, France and 1 more country
Ages 18+
Biotronik AG · Sites in Belgium, Austria, France and 5 more countries
Ages 18+
CSL Behring · Sites in Belgium, United States, Argentina and 32 more countries
Ages 18+
iVascular S.L.U. · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 286 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 120 across the 58 interventional studies, 300 across the 27 observational. Of the 62 that completed or were terminated, 16 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 85 have an industry lead sponsor. The 10 most frequent:
KANDO Research is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
KANDO Research has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT04349657KANDO ResearchA Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy | 2027-05 |
| NCT06832631OrbusNeichVITUS Post-Market Registry | 2027-06 |
| NCT07322913IntervascularIntervascular Post-Market Clinical Follow-Up (PMCF) Registry | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 85 studies in Peripheral Arterial Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The SUPERSURG RCT trial investigates the efficacy and safety of the endovascular treatment of stenosis or restenosis in the common femoral artery (CFA) of patients presenting with Rutherford classification 2,3 or 4 with a Supera Vascular Mimetic Implant of Abbott, compared to classic surgical common femoral artery endarterectomy. The Supera Vascular Mimetic Implant has an interwoven design and has a high crush resistance and is, when correctly implanted, an ideal stent to treat eccentric calcified plaques in the CFA.
An expected total of 143 patients will be treated with the Vascular Mimetic Implant of Abbott and compared to a control group of another 143 patients that will be treated with classic surgical endarterectomy of the common femoral artery. Assignment to the treatment groups will be at random.
Patients will be invited for a follow-up visit at 1, 6, 12, 24 and 36 months post-procedure.
The primary efficacy endpoint is defined as follows: freedom from clinically-driven target lesion revascularization and binary restenosis at 12 months. The primary safety endpoint is defined as follows: a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularisation and wound related complications through 30 days post-index procedure.
The secondary endpoints are defined as technical success, primary patency in the deep femoral artery, primary patency in the target lesion, target lesion revascularisation, target vessel revascularisation, binary restenosis, duration of initial hospital stay, sustained clinical improvement, change of walking impairment questionnaire score from baseline, change in target limb Rutherford classification, change in target limb ABI/TBI from baseline, all cause death, thrombosis at the target lesion through 6, 12, 24 and 36 months post-procedure.
The objective of this clinical investigation is to assess the safety and efficacy of the Supera Vascular Mimetic Implant for the treatment of stenotic or restenotic lesions of the common femoral artery. Furthermore, a non-inferiority hypothesis in terms of efficacy and a superiority in terms of safety will be tested with the endovascular treatment with Supera compared to surgical endarterectomy of the common femoral artery.
The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.
Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI) or toe-brachial index (TBI), blood sample test (complete blood count, comprehensive metabolic panel and if applicable pregnancy test) and a walking impairment questionnaire. Randomization will also occur prior to the procedure.
During the procedure patients that are randomized within the endarterectomy group will be treated according to the institutions standard of care. For patients that are randomized within the Supera arm, the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. Pre-dilatation of the target lesion with an uncoated PTA-balloon is mandatory and will be followed by stenting with the Supera stent according to the instructions for use. Postdilatation of the stent is allowed but not mandatory.
The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. The patients will be invited for the following required follow-up visits at 1, 6, 12, 24 and 36 months. During these visit the following data will be collected: medication record, physical exam, target limb ABI/TBI and Rutherford classification, duplex ultrasound of target vessel, walking impairment questionnaire and possible adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
Device: Supera Peripheral Stent System treatment group
These patients will be treated surgically with endarterectomy
Procedure: Endarterectomy treatment group
Percutaneous endovascular stenting with the Supera Peripheral Stent System
Surgical treatment through endarterectomy
Primary efficacy endpoint at 12 months: Primary patency
To demonstrate the non-inferior efficacy in the group treated with the Supera stent compared to the group treated with endarterectomy for the treatment of atherosclerosis in the common femoral artery (CFA). Efficacy is defined as primary patency: freedom from restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by an independent DUS core lab in CFA without a previous target lesion revascularization through 12 months post-index procedure.
Time frame: 12 months post-index-procedure
Primary safety endpoint at 30 days post-index procedure
To demonstrate superior safety in the group treated with the Supera stent compared to the endarterectomy group for the treatment of atherosclerosis in the CFA. Safety is defined as a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularization (TLR) and wound-related complications (haematoma, seroma, lymphocele, lymphatic leaks with lymphatic fistula, surgical site infections (SSIs) (Szilagyi grade I, II and III)).
Time frame: 30 days post-index-procedure
Technical success: post-procedure residual stenosis <30%
Supera group: Defined as the ability to cross and stent the lesion to achieve residual angiographic stenosis no greater than 30%. Endarterectomy group: defined as the ability to remove the atherosclerotic plaque with or without patch (interposition grafts are not allowed). In the imaging subcohort the endarterectomy is considered successful when a residual stenosis no greater than 30% per visual estimation is confirmed.
Time frame: Index procedure
Primary patency in the deep femoral artery (DFA), post-index procedure and at 6-, 12-, 24- and 36-months post-index procedure
Primary patency in the DFA is defined as freedom from an occlusion in the DFA as assessed by PSV-values. This PSV-value will be assessed pre-procedure, post-procedure, 6 months and 12 months post-index procedure. At 12 months, the PSV-value will be core-lab controlled.
Time frame: 6, 12, 24 and 36 months post-index-procedure
Primary patency at 6, 24 and 36 months
Primary patency is a composite of freedom from clinically-driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by DUS in CFA) through 6 months post-index procedure
Time frame: 6, 24 and 36 months post-index-procedure
TLR at 6-, 12-, 24- and 36-months post-index procedure
TLR is defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure
Time frame: 6, 12, 24 and 36 months post-index-procedure
TVR at 6-, 12-, 24- and 36-months post-index procedure
Target vessel revascularization (TVR) is defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure
Time frame: 6, 12, 24 and 36 months post-index-procedure
Binary restenosis at 6, 12, 24 and 36 months
Binary restenosis is defined as restenosis confirmed by DUS PSVR ≥2.4 or ≥50% stenosis as assessed by angiographic and DUS images. At 12 months, the images will be core lab controlled
Time frame: 6, 12, 24 and 36 months post-index-procedure
Duration of initial hospitalisation stay
Number of hours/days of the initial hospitalisation stay.
Time frame: Up to 4 weeks
Sustained clinical improvement at 6-, 12-, 24- and 36-months post-index procedure
Clinical improvement is defined as freedom from major target limb amputation, TVR, worsening target limb Rutherford class (compared to baseline) and decrease in target limb ankle brachial index (ABI) or toe brachial index (TBI) ≥0.15 (compared to baseline)
Time frame: 6, 12, 24 and 36 months post-index-procedure
Change in Walking Impairment Questionnaire (WIQ) score from baseline to 6, 12, 24 and 36 months
change in walking impairment questionnaire (WIQ) score from baseline to 6 and 12 months. The WIQ consists of 6 sections each consisting of multiple questions. Each question is scored from 0 to 4 (0 meaning a lot of problems and 4 no problems at all). The scores per section are summed up and recalculated to percentages (100% meaning very good and 0% meaning very bad). All the sections are averaged to give the final WIQ-score.
Time frame: 6, 12, 24 and 36 months post-index-procedure
Change in target limb Rutherford class from baseline to 6, 12, 24 and 36 months
Change in target limb Rutherford class from baseline to 6, 12, 24 and 36 months
Time frame: 6, 12, 24 and 36 months post-index-procedure
Change in target limb resting ABI or TBI from baseline to 6, 12, 24 and 36 months
Change in target limb resting ABI or TBI from baseline to 6, 12, 24 and 36 months
Time frame: 6, 12, 24 and 36 months post-index-procedure
All cause death at 6, 12, 24 and 36 months
All cause death at 6, 12, 24 and 36 months
Time frame: 6, 12, 24 and 36 months post-index-procedure
Thrombosis at the target lesion at 6, 12, 24 and 36 months
Thrombosis at the target lesion at 6, 12, 24 and 36 months
Time frame: 6, 12, 24 and 36 months post-index-procedure
Started May 2020 (actual). Primary completion is estimated for May 2027, 84 months after the start.
Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 84 months is above that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
KANDO Research